RecruitingEarly Phase 1NCT06119490
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Studying Toxic epidermal necrolysis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peng Zhang
- Intervention
- Abrocitinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Department of Dermatology, the First Affiliated Hospital of Fujian Medical University., Fuzhou, Fujian, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06119490 on ClinicalTrials.gov